Board: Mylan Failed To Prove Novo Nordisk Patents Are Obvious
ALEXANDRIA, Va. — The Patent Trial and Appeal Board denied institution of inter partes review (IPR) of several claims in two challenged Novo Nordisk A/S patents directed to a modified peptide...To view the full article, register now.
Already a subscriber? Click here to view full article